One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1182/blood.v126.23.4060.4060
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Dec 3, 2015 |
 Citations: 33 |
Affiliation: Guy's and St Thomas' NHS Foundation Trust, Délégation Paris 7, Hôpital Saint-Louis, Université Paris Cité, Otto-von-Guericke University Magdeburg, University of Florence, Ospedale di Circolo e Fondazione Macchi, Ollscoil na Gaillimhe – University of Galway, St. James's Hospital, Azienda ospedaliera "Bianchi-Melacrino-Morelli", Johannes Gutenberg University Mainz, German Cancer Research Center, Heidelberg University, Tris Pharma (United States), Novartis (Switzerland), Institut Gustave Roussy
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
